Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloma

Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma

Bone Marrow Transplantation volume 26, pages 45–50 (2000)Cite this article

Abstract

The optimal timing of stem cell transplantation for multiple myeloma is controversial. Late stem cell collection is undesirable because of the inability to mobilize stem cells. We report on 64 recipients of stem cells collected within 1 year after diagnosis, none of whom had transplantation in plateau phase of their disease. Patients seen within 12 months after diagnosis received four cycles of standard vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy and then had stem cells mobilized. Patients were then placed on maintenance vincristine, BCNU, melphalan, cyclophosphamide, and prednisone or melphalan and prednisone chemotherapy for 12 cycles. At the sign of first progression, transplantation occurred. Fourteen patients were refractory to VAD chemotherapy, 20 relapsed on maintenance chemotherapy, and 30 relapsed off chemotherapy. The time to platelet engraftment was not affected by the duration of stem cell cryopreservation or extent of chemotherapy exposure after mobilization. The complete response rate was 34%. The actuarial median survival from initial diagnosis, from transplant day 0, and post-transplant progression-free survival was 51, 20 and 11.4 months, respectively. The patient status at transplantation and percentage of plasma cells circulating in the blood at apheresis influenced post-transplant survival; circulating plasma cells, status at transplantation and plasma cell labeling index influenced progression-free survival. Response duration was shorter in patients relapsing on chemotherapy. Bone Marrow Transplantation (2000) 26, 45–50.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Attal M, Harousseau JL, Stoppa AM et al. for the Intergroupe Français du Myelome A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma New Engl J Med 1996 335: 91–97

    Article  CAS  PubMed  Google Scholar 

  2. Barlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma Blood 1997 89: 789–793

    CAS  PubMed  Google Scholar 

  3. Alegre A, Tomas JF, Martinez-Chamorrow C et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone Bone Marrow Transplant 1997 20: 211–217

    Article  CAS  PubMed  Google Scholar 

  4. Alegre A, Diaz-Mediavilla J, San-Miguel J et al. for the Spanish Registry for Transplant in MM (Grupo Espanol de Trasplante Hematopoyetico-GETH) and PETHEMA Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry Bone Marrow Transplant 1998 21: 133–140

    Article  CAS  PubMed  Google Scholar 

  5. Huang YW, Vitetta ES . Immunotherapy of multiple myeloma Stem Cells 1995 13: 123–134

    Article  CAS  PubMed  Google Scholar 

  6. Powles R, Raje N, Horton C et al. Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy Leuk Lymphoma 1996 21: 421–427

    Article  CAS  PubMed  Google Scholar 

  7. Fermand JP, Ravaud P, Chevret S et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial Blood 1998 92: 3131–3136

    CAS  PubMed  Google Scholar 

  8. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients Blood 1995 85: 588–596

    CAS  PubMed  Google Scholar 

  9. Lemoli RM, Cavo M, Fortuna A . Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma J Hematother 1996 5: 339–349

    Article  CAS  PubMed  Google Scholar 

  10. Tricot G, Gazitt Y, Leemhuis T et al. Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma Blood 1998 91: 4489–4495

    CAS  PubMed  Google Scholar 

  11. Barlogie B, Smith L, Alexanian R . Effective treatment of advanced multiple myeloma refractory to alkylating agents New Engl J Med 1984 310: 1353–1356

    Article  CAS  PubMed  Google Scholar 

  12. Committee of the Chronic Leukemia Myeloma Task Force, National Cancer Institute . Proposed guidelines for protocol studies. II. Plasma cell myeloma Cancer Chemother Rep 1968 1: 17–39

    Google Scholar 

  13. Case DC Jr, Lee DJ III, Clarkson BD . Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol Am J Med 1977 63: 897–903

    Article  PubMed  Google Scholar 

  14. Oken MM, Harrington DP, Abramson N et al. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479 Cancer 1997 79: 1561–1567

    Article  CAS  PubMed  Google Scholar 

  15. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481

    Article  Google Scholar 

  16. Cox DR . Regression models and life-tables JR Stat Soc [B] 1972 34: 187–202

    Google Scholar 

  17. Bladé J, Samson D, Reece D et al. (Myeloma Subcommittee of the EBMT (European Group for Blood and Marrow Transplant)). Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation BrJ Haematol 1998 102: 1115–1123

    Article  Google Scholar 

  18. Kantarjian HM, Smith TL, O'Brien S et al . and the Leukemia Service Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy Ann Intern Med 1995 122: 254–261

    Article  CAS  PubMed  Google Scholar 

  19. Gratwohl A, Hermans J, Goldman JM et al. for the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation Lancet 1998 352: 1087–1092

    Article  CAS  PubMed  Google Scholar 

  20. McGlave PB, De Fabritiis P, Deisseroth A et al. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups Lancet 1994 343: 1486–1488

    Article  CAS  PubMed  Google Scholar 

  21. Sawyers CL . Chronic myeloid leukemia New Engl J Med 1999 340: 1330–1340

    Article  CAS  PubMed  Google Scholar 

  22. Zittoun RA, Mandelli F, Willemze R et al . for the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia New Engl J Med 1995 332: 217–223

    Article  CAS  PubMed  Google Scholar 

  23. Champlin RE, Ho WG, Gale RP et al. Treatment of acute myelogenous leukemia. A prospective controlled trial of bone marrow transplantation vs consolidation chemotherapy Ann Intern Med 1985 102: 285–291

    Article  CAS  PubMed  Google Scholar 

  24. Dighiero G, Maloum K, Desablens B et al . for the French Cooperative Group on Chronic Lymphocytic Leukemia Chlorambucil in indolent chronic lymphocytic leukemia New Engl J Med 1998 338: 1506–1514

    Article  CAS  PubMed  Google Scholar 

  25. Bjorkstrand BB, Ljungman P, Svensson H et al. Allogeneic bone marrow transplantation vs autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation Blood 1996 88: 4711–4718

    CAS  PubMed  Google Scholar 

  26. Gertz MA, Lacy MQ, Inwards DJ et al. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma Bone Marrow Transplant 1999 23: 221–226

    Article  CAS  PubMed  Google Scholar 

  27. Rajkumar SV, Fonseca R, Lacy MQ et al. Autologous stem cell transplantation for relapsed and primary refractory myeloma Bone Marrow Transplant 1999 23: 1267–1272

    Article  CAS  PubMed  Google Scholar 

  28. Couban S, Stewart AK, Loach D et al. Autologous and allogeneic transplantation for multiple myeloma at a single centre Bone Marrow Transplant 1997 19: 783–789

    Article  CAS  PubMed  Google Scholar 

  29. Witzig TE, Gertz MA, Pineda AA et al. Detection of monoclonal plasma cells in the peripheral blood stem cell harvests of patients with multiple myeloma Br J Haematol 1995 89: 640–642

    Article  CAS  PubMed  Google Scholar 

  30. Prince HM, Imrie K, Sutherland DR et al. Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collections Br J Haematol 1996 93: 142–145

    Article  CAS  PubMed  Google Scholar 

  31. Watts MJ, Sullivan AM, Leverett D et al. Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization J Clin Oncol 1998 16: 1554–1560

    Article  CAS  PubMed  Google Scholar 

  32. Vesole DH, Tricot G, Jagannath S et al. Autotransplants in multiple myeloma: what have we learned? Blood 1996 88: 838–847

    CAS  PubMed  Google Scholar 

  33. Vesole DH, Barlogie B, Jagannath S et al. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants Blood 1994 84: 950–956

    CAS  PubMed  Google Scholar 

  34. Stewart FM . Indications and relative indications for stem cell transplantation in non-Hodgkin's lymphoma Leukemia 1993 7: 1091–1094

    CAS  PubMed  Google Scholar 

  35. Dimopoulos MA, Alexanian R, Przepiorka D et al. Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma Blood 1993 82: 2324–2328

    CAS  PubMed  Google Scholar 

  36. Billadeau D, Van Ness B, Kimlinger T et al. Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma Blood 1996 88: 289–296

    CAS  PubMed  Google Scholar 

  37. Johnson RJ, Owen RG, Smith GM et al. Peripheral blood stem cell transplantation in myeloma using CD34 selected cells Bone Marrow Transplant 1996 17: 723–727

    CAS  PubMed  Google Scholar 

  38. Lemoli RM, Fortuna A, Raspadori D et al. Selection and transplantation of autologous hematopoietic CD34+ cells for patients with multiple myeloma Leuk Lymphoma 1997 26: (Suppl. 1) 1–11

    Article  PubMed  Google Scholar 

  39. Stewart AK, Schiller G, Vescio R et al. CD34 selection does not prolong disease free or overall survival in myeloma patients undergoing autologous stem cell transplant: results of a phase III study Blood 1999 94: (Suppl. 1) 714a (Abstr.)

    Google Scholar 

  40. Bataille R, Boccadoro M, Klein B et al. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system Blood 1992 80: 733–737

    CAS  PubMed  Google Scholar 

  41. Reichardt VL, Okada CY, Liso A et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma – a feasibility study Blood 1999 93: 2411–2419

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN, USA

    MA Gertz, MQ Lacy, DJ Inwards, DA Gastineau, A Tefferi, TE Witzig, PR Greipp & MR Litzow

  2. Division of Transfusion Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN, USA

    DA Gastineau

  3. Division of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN, USA

    MG Chen

  4. Department of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Foundation, Rochester, MN, USA

    PR Greipp

Authors
  1. MA Gertz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. MQ Lacy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. DJ Inwards
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. DA Gastineau
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Tefferi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. MG Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. TE Witzig
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. PR Greipp
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. MR Litzow
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gertz, M., Lacy, M., Inwards, D. et al. Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Bone Marrow Transplant 26, 45–50 (2000). https://doi.org/10.1038/sj.bmt.1702445

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702445

Keywords

This article is cited by

Search

Advanced search

Quick links